Munich - Delayed Quote EUR

10x Genomics Inc (1KJ.MU)

7.24

+0.16

+(2.29%)

At close: April 25 at 8:04:35 AM GMT+2

10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company

PR Newswire 11 days ago

TXG
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most countries, sparking renewed optimism amid ongoing trade talks. The major stock indices rose as investors, growing impatient of seemingly irrational tariff actions, welcomed the pause as a sign of a more measured path forward.

StockStory 16 days ago

MRNA

TXG

PACB
Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers.

StockStory 16 days ago

TXG

TECH

WAT
We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 29 days ago

TXG
These 10 biotech companies are changing how we discover new drugs and treat complex diseases

The 10 most innovative biotech companies of 2025 are leveraging AI to find new drugs, match patients with the best treatments, and even support biodiversity research.

FastCompany last month

PTGX

TXG

WGSWW
2 Reasons to Sell TXG and 1 Stock to Buy Instead

What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many shareholders. This was partly due to its softer quarterly results and might have investors contemplating their next move.

StockStory last month

TXG
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed - a week before trial was to start - to a worldwide permanent injunction that prevents it from making, using, selling or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this cons

PR Newswire last month

TXG
1 Stock Under $50 on Our Watchlist and 2 to Ignore

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

StockStory last month

SHYF

TXG

CFLT
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale. In addition, the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology.

PR Newswire last month

TXG
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m. Eastern Time.

PR Newswire 2 months ago

TXG
10x Genomics Full Year 2024 Earnings: EPS Misses Expectations

10x Genomics ( NASDAQ:TXG ) Full Year 2024 Results Key Financial Results Revenue: US$610.8m (down 1.3% from FY 2023...

Simply Wall St. 2 months ago

TXG
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30). The single-cell and spatial biology company reported quarterly sales of $165.02 million, down 10% year over year, beating the consensus of $159.39 million. Gross margin was 67% for the fourth quarter of 2024 compared to 63% a year ago, primarily due to product mix changes. 10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This i

Benzinga 2 months ago

TXG
Trump’s Cuts to Medical Research Are Hurting These Stocks

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively.

Barrons.com 2 months ago

ILMN

TXG
Why 10x Genomics (TXG) Shares Are Falling Today

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full-year revenue guidance fell short of Wall Street's estimates. Revenue declined by 10% year on year, reflecting ongoing weakness in demand, particularly in instrument sales, though consumables performed better. Despite the revenue decline, gross margins improved, benefiting from a more favorable product m

StockStory 2 months ago

TXG
10x Genomics Shares Tumble on Fear Over Cuts to NIH

A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

Barrons.com 2 months ago

TXG
Q4 2024 10X Genomics Inc Earnings Call

Q4 2024 10X Genomics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

TXG
10x Genomics Inc (TXG) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...

Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to drive future growth.

GuruFocus.com 2 months ago

TXG
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 2 months ago

TXG
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

TXG

ENOV
10x Genomics: Q4 Earnings Snapshot

PLEASANTON, Calif. AP) — 10x Genomics Inc. TXG) on Wednesday reported a loss of $49 million in its fourth quarter.

Associated Press Finance 2 months ago

TXG

Performance Overview

Return	1KJ.MU	S&P 500 (^GSPC)
YTD	-48.57%	-6.06%
1-Year	-72.18%	+9.44%
3-Year	-86.11%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

10x Genomics Inc (1KJ.MU)

10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks

We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth

These 10 biotech companies are changing how we discover new drugs and treat complex diseases

2 Reasons to Sell TXG and 1 Stock to Buy Instead

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

1 Stock Under $50 on Our Watchlist and 2 to Ignore

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

10x Genomics Full Year 2024 Earnings: EPS Misses Expectations

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties

Trump’s Cuts to Medical Research Are Hurting These Stocks

Why 10x Genomics (TXG) Shares Are Falling Today

10x Genomics Shares Tumble on Fear Over Cuts to NIH

Q4 2024 10X Genomics Inc Earnings Call

10x Genomics Inc (TXG) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...

Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings

10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates

10x Genomics: Q4 Earnings Snapshot

Performance Overview